XML 102 R39.htm IDEA: XBRL DOCUMENT v3.25.3

Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			9 Months Ended
	Jun. 30, 2024	Sep. 30, 2025	Jun. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Collaborative and license agreements
Cash outflows related to acquisitions and investments					$ (4,076)	$ (1,232)
Acquired IPR&D and milestones		$ 2,680		$ 82	3,751	1,183
Collaborative arrangement
Collaborative and license agreements
Research and development milestone expenses		65		0	185	95
Ichnos Glenmark Innovation, Inc.
Collaborative and license agreements
Acquired IPR&D and milestones		700
Ichnos Glenmark Innovation, Inc. | Collaborative arrangement
Collaborative and license agreements
Potential Payments under Agreement Certain Milestones		1,200			1,200
Capstan Therapeutics, Inc.
Collaborative and license agreements
Acquired IPR&D and milestones		1,900
Cash consideration paid to shareholders		2,100
Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards		187
ADARx Pharmaceuticals, Inc.
Collaborative and license agreements
Acquired IPR&D and milestones			$ 335
ADARx Pharmaceuticals, Inc. | Collaborative arrangement
Collaborative and license agreements
Potential Payments under Agreement Certain Milestones			7,500
Option fees and exercise payments			385
Gubra A/S
Collaborative and license agreements
Acquired IPR&D and milestones			350
Gubra A/S | Collaborative arrangement
Collaborative and license agreements
Potential Payments under Agreement Certain Milestones			$ 1,900
Celsius Therapeutics
Collaborative and license agreements
Cash consideration paid to shareholders	$ 250
Other Collaboration Arrangements | Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones		$ 2,615		$ 82	$ 3,566	$ 1,088

X

- Definition

Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards

+ References

No definition available.

+ Details

Name:	abbv_CashSettledPostClosingExpenseForEmployeeIncentiveAndCompensationAwards
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Option fees and exercise payments

+ References

No definition available.

+ Details

Name:	abbv_OptionFeesAndExercisePayments
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Research and Development Milestone Expenses

+ References

No definition available.

+ Details

Name:	abbv_ResearchAndDevelopmentMilestoneExpenses
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of cash outflow to acquire investments classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-21

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_IchnosGlenmarkInnovationInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_CapstanTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_ADARxPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_GubraASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_CelsiusTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: